Postprint online available 09/2019 Open Access Green as soon as is submitted to ZB.
High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation.
Ann. Hematol. 98, 93-100 (2019)
Venous thromboembolism (VTE) is a major burden in patients with BCR-ABL-negative myeloproliferative neoplasms (MPN). In addition to cytoreductive treatment anticoagulation is mandatory, but optimal duration of anticoagulation is a matter of debate. In our single center study, we retrospectively included 526 MPN patients. In total, 78 of 526 MPN patients (14.8%) had 99 MPN-associated VTE. Median age at first VTE was 52.5years (range 23-81). During a study period of 3497years, a VTE event rate of 1.7% per patient/year was detected. 38.4% (38/99) of all VTEs appeared before or at MPN diagnosis and 55.6% (55/99) occurred at uncommon sites like splanchnic or cerebral veins. MPN patients with VTEs were significantly more female (p=0.028), JAK2 positive (p=0.018), or had a polycythemia vera (p=0.009). MPN patients without VTEs were more often CALR positive (p=0.023). Total study period after first VTE was 336years with 20 VTE recurrences accounting for a recurrence rate of 6% per patient/year. In 36 of 71 MPN patients with anticoagulation therapy after first VTE event (50.7%), prophylactic anticoagulation was terminated after a median time of 6months (range 1-61); 13 of those 36 patients (36.1%) had a VTE recurrence after a median of 13months (range 4-168). In contrast, only three of 35 (8.6%) patients with ongoing anticoagulation had a VTE recurrence (p=0.0127). Thus, termination of prophylactic anticoagulation was associated with a significantly higher risk of VTE recurrence. Our data suggest that in MPN patients with VTE, a prolonged duration of anticoagulation may be beneficial.
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Keywords Myeloproliferative Neoplasms ; Recurrent Venous Thromboembolism ; Anticoagulation Therapy; Essential Thrombocythemia; Polycythemia-vera; Oral Rivaroxaban; Thrombosis; Myelofibrosis; Epidemiology; Prophylaxis; Hydroxyurea; Anagrelide; Intensity
Institute(s) Institute of Computational Biology (ICB)